A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
If you are reading and signing this form on behalf of a potential participant, please note: Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to find the highest tolerable dose level of ADCT-402 that can be given to patients with acute lymphoblastic leukemia (ALL). Researchers also want to learn if that dose level can help to control ALL. The safety of ADCT-402 will also be studied. This is the first study using ADCT-402 in humans.
Treatment Location: N/A
IRB Review and Approval Date: 05/05/2016
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: